mRNA player BioNTech has announced plans to identify a new lab and production in Israel, as part of a partnership with the Weizmann Institute of Science.
Biotechnology is an “mRNA Center of Excellence” at the Weizmann Science Park in Ness Ziona, where it will work with scientists from the Weizmann Institute on a variety of diseases, from cancer to infectious diseases to neurodegenerative diseases. In addition, BioNTech announced Wednesday that it will build an mRNA production facility based on its BioNtainers, which are container-sized modular assemblies supplied to pump vaccines and mRNA-based therapies.
The production facility will be used to expand investigational cancer treatments and “Israel’s ability to respond to potential health threats,” the company said. However, the position and location of the site are still unclear. Endpoints News reached out to BioNTech but did not get a response at press time.
BioNTech in the Weizmann Science Park is expected to host around 60 researchers starting later this year. The company will also work with Weizmann scientists in the laboratories of the Israel-based Rehovot school.
“Our initiative aims to foster collaborations with the most sensitive scholars to advance multidisciplinary studies and increase the progression of cutting-edge responses to address some of the world’s most urgent fitness challenges,” CEO Uğur Şahin said in a statement.
BioNTech has broadened its outlook in recent years, revealing plans for new production sites in Singapore and the Rwandan capital of Kigali. In February, he announced the finishing touch to the structure of a new plasmid DNA facility near his home in Marburg, Germany. BioNTech invested 40 million euros ($42. 4 million) in the facility.
Key things to remember:
Novo Nordisk expands its R business
The company announced the creation of more than two hundred new jobs, adding approximately 150 for research in knowledge sciences, biology or chemistry and R
But now that Boston will be R’s
Unlock this story right away and sign up to have over 161,700 biopharmaceutical professionals read Endpoints daily, and it’s free.
Generic drugmaker Akorn Pharmaceuticals has filed for bankruptcy and will sell its services across the United States, liquidate its assets and shut down operations, it said in a court filing.
According to an undated letter from CEO Douglas Boothe via the Illinois Herald news site.
Unlock this story right away and sign up to have over 161,700 biopharmaceutical professionals read Endpoints daily, and it’s free.
Emil Kakkis, CEO of rare disease drug maker Ultragenyx Pharmaceuticals, sat down with Endpoints News in Washington, D. C. to talk about the industry’s latest struggles around the emergence of rare and ultra-rare disease drugs, the need for the Orphan Drug Act 2. 0, and why the FDA wants to qualify more biomarkers and pave the way for accelerated approval.
At least 30 rare disease drug systems were shut down over the past year, Kakkis said, noting that the approval procedure is more complicated in some cases because the FDA raises the bar or the money is too high.
Unlock this story right away and sign up to have over 161,700 biopharmaceutical professionals read Endpoints daily, and it’s free.
USA. The U. S. government has contributed at least $31. 9 billion in public investment to the progression of mRNA-based Covid-19 vaccines, according to a new BMJ study.
That at least $337 million in the 3 decades leading up to the pandemic, wrote seven researchers from the Brigham and Women’s Program On Regulation, Therapeutics, And Law (PORTAL).
For co-author and number one care physician Hussain Lalani, the study began as a way to understand the origins of mRNA vaccines and make patients realize that Covid shots weren’t created overnight.
Alfredo Najá Domingos’ prostate cancer is spreading. Malignant cells permeated his bones, kidneys, lungs and liver, and in December his oncologist told him he didn’t want to continue chemotherapy treatment.
But there was a new remedy he could try: targeted radiation called Pluvicto, if he gets it in time. The Moffitt Cancer Center and Mayo Clinic in Florida, not far from Domingos and his family, said he would have to wait between three-and-a-half and four months to get the remedy. His wife, Nora Flor, said she and her sister had called at least 30 centers in the U. S. U. S. in search of the drug.
Unlock this article and others by subscribing to one of our paid plans.
Issi Rozen is as deeply rooted in the gene-editing box as he is in the bustling biotech hub of Cambridge, MA. As Broad’s chief commercial officer and chief strategy officer for a decade, he has worked with all the big names in a clinical field. which promises to interrupt the healing box, eventually. He is even a co-founder of Verve, which carries the banner of fundamental publishing.
Unlock this article and others by subscribing to one of our paid plans.
In another effort to investigate pharmaceutical intermediaries and their impact on physical care prices, House Oversight Committee Chairman James Comer (R-KY) is launching an investigation into pharmacy benefits manager (PBM) tactics that are hurting patient care and expanding. prices for consumers. “
He is one of many politicians advocating for greater transparency in PBMs, the middlemen who negotiate discounts with drug brands in exchange for formulary coverage.
The virtual explosion of healthcare and media in recent years has led to an avalanche of pharmaceutical marketers with large amounts of data, but without enough information. Publicis Health is launching a new practice targeting the pharmaceutical industry to help replace that.
Called Insagic, the purpose of the new company is to make patient and physician knowledge actionable. While it may sound simple, Insagic’s list of features is extensive, adding AI-assisted patient and physician analytics, audience segmentation and discovery, complex targeting, persuasion modeling, intervention design, and end-result optimization.
Unlock this story right away and sign up to have over 161,700 biopharmaceutical professionals read Endpoints daily, and it’s free.
© Endpoints Company 2023
We will email you a link to set a new password. Please note that this link is for single use and is valid for 24 hours.